Moderna Inc. (MRNA) Stock
NASDAQMRNA has an Alpha Score of 35 out of 100 (weak), computed on Nov 21, 2026 from 2 of 4 sub-scores. 7 members of Congress disclosed 23 trades in MRNA since 2021: 7 purchases and 16 sales, most recently Gilbert Cisneros (purchase, Oct 20, 2026). 6 of the hedge funds AlphaScala tracks reported MRNA in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $749.84M. Company insiders reported 0 open-market buys and 12 sales on SEC Form 4 in the 90 days to Nov 20, 2026.
What is MRNA's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 21, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Moderna Inc. (MRNA)?
Most recent: Gilbert Cisneros (purchase, Oct 20, 2026); records start Jan 8, 2021.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-10-20 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-09-24 | partial sale | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-08-19 | partial sale | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-08-19 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-02-25 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-01-15 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-02-01 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.
See all MRNA political trades →Which hedge funds own MRNA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.89M | $749.84M | +788% |
| Citadel Ken Griffin | 116K | $22.37M | -61% |
| Point72 Steve Cohen | 109K | $20.92M | NEW |
| Bridgewater Associates Ray Dalio | 72K | $13.93M | +528% |
| D.E. Shaw David Shaw | 26K | $5.04M | +5% |
| Hussman Investment Trust John Hussman | 6K | $1.21M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Moderna Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 17, 26 | Hoge Stephen | President | SELL | 34.0K | $7.2M |
| Nov 17, 26 | Hoge Stephen | President | SELL | 5.1K | $1.1M |
| Nov 17, 26 | Hoge Stephen | President | SELL | 157 | $34K |
| Nov 16, 26 | Hoge Stephen | President | SELL | 39.2K | $8.6M |
| Oct 15, 26 | Hoge Stephen | President | SELL | 39.1K | $8.6M |
| Oct 14, 26 | Hoge Stephen | President | SELL | 38.8K | $8.3M |
| Oct 14, 26 | Hoge Stephen | President | SELL | 450 | $96K |
| Sep 15, 26 | Hoge Stephen | President | SELL | 40.3K | $5.9M |
| Sep 14, 26 | Hoge Stephen | President | SELL | 40.3K | $5.8M |
| Sep 10, 26 | Mock James M | Chief Financial Officer | SELL | 19.8K | $2.7M |
SEC Form 4 filings as of Nov 20, 2026
See cluster-buy signals across all tickers →What are MRNA's key statistics?
Key statistics as of Nov 11, 2026
How does MRNA's valuation compare with the Healthcare sector?
| Metric | MRNA | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -110.46% | 3.62% | 218 |
| Return on equity | -37.62% | 3.50% | 249 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.
AlphaScala analysis on MRNA
Latest 1MRNA price chart
Powered by TradingViewWhat does Moderna Inc. do?
Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary function centers on creating innovative therapeutics and vaccines using mRNA technology, targeting a broad spectrum of diseases including infectious, oncological, rare, and cardiovascular conditions. Key products include Spikevax, an mRNA-based COVID-19 vaccine, alongside mRESVIA for respiratory syncytial virus (RSV), and investigational vaccines for seasonal influenza, cytomegalovirus, Epstein-Barr virus, norovirus, Zika, and bacterial diseases like Lyme. In oncology, it advances individualized neoantigen therapies and immune modulation treatments; for rare diseases, it develops therapies for propionic acidemia, glycogen storage disease, and cystic fibrosis. With a pipeline of over 40 clinical-stage products, Moderna, Inc. plays a pivotal role in the biopharmaceutical sector, driving advancements in precision medicine and public health responses to pandemics and endemic threats through its mRNA platform.